Tesamorelin
22.2K
Volume
+3900%
Growth
exploding
About the Topic
This synthetic peptide is utilized to decrease excess abdominal fat in HIV-infected patients with lipodystrophy by promoting growth hormone production. It is marketed under the brand name Egrifta and is distinguished by its specific application in managing lipodystrophy associated with HIV. The primary beneficiaries of this treatment are HIV-infected individuals experiencing lipodystrophy-related abdominal fat accumulation.
Tesamorelin was discovered on April 30th 2025 and it currently has a search volume of 22.2K with a growth of +3900%.
Key Indicators
Growth
- Exploding
- Regular
- Peaked
Speed
- Exponential
- Constant
- Stationary
Seasonality
- High
- Medium
- Low
Volatility
- High
- Average
- Low
Members Only
Try Exploding Topics Pro
Get Free, Unlimited Access for 7 Days.
Categories
Save this topic and build your own trend dashboard.
Available with Exploding Topics Pro, try it now.
1.1M+ trends in our growing database.